切伦科夫辐射稀土材料发光用于乳腺癌淋巴成像

High invasion metastatic malignant breast cancer influencing women's health. In order to identifying, positioning, excising the metastatic lymph node during surgery process, is the difficult clinical problems. A powerful tool of tumor targeted radionuclide molecular probes could not only use for PET and SPECT imaging, but also Cerenkov radiation luminescence imaging. However, the emission of Cerenkov radiation are in UV – Blue light, resulting in lower penetration depth for optical imaging in vivo. Herein, the project will study on characteristics and principles of Cerenkov radiation rare-earth nanoparticles NaYF4:xGd, yLn (Ln: Eu, Er, Pr, Dy, x = 0 ~ 80%, y = 0.1 ~ 20%) for red emission. Based lymphatic imaging studies earlier, we design a new collaborative multi-step strategy of radionuclide molecular probes Cerenkov radiation rare-earth nanoparticles luminescence imaging to identify metastatic lymph node by breast cancer model: After the peritumoral injection rare-earth nanoparticles draining into lymph nodes, the intravenous injection of targeting radionuclide molecular probes Cerenkov radiation rare earth luminescence to identify metastatic lymph node. Using this strategy for cancer " visual treatment " would provide a new theory and technical method.

高侵蚀转移性恶性乳腺癌危害女性健康，在手术中识别、定位、清除被肿瘤侵蚀的淋巴是临床医学研究的重点和难点。靶向性的核素分子影像探针是一种有力的工具，能够实现肿瘤及肿瘤转移的位点的PET和SPECT成像，同时，可以利用核素切伦科夫辐射发光进行原位的光学成像。但是核素切伦科夫辐射发光以紫外-蓝光为主，生物光学成像效率较低。为此，本项目研究核素切伦科夫辐射稀土纳米材料NaYF4:xGd, yLn（ Ln：Eu，Er，Pr，Dy，x = 0~80%，y = 0.1~20%）发射红光的特性和原理；并在稀土发光材料淋巴成像研究的基础上，构建高转移的乳腺癌模型，设计一种多步协同成像策略：先在瘤周注射稀土发光纳米材料靶向多个淋巴位点，通过核素分子探针靶向肿瘤侵蚀淋巴结，以核素切伦科夫辐射激发淋巴中稀土发光，来区分稀土材料随引流进入的淋巴结是否为肿瘤转移淋巴结。利用该策略为肿瘤的“可视化诊疗”提供依据。

高侵蚀转移性恶性乳腺癌危害女性健康，在手术中识别、定位、清除被肿瘤侵蚀的淋巴是临床医学研究的重点和难点。靶向性的核素分子影像探针是一种有力的工具，能够实现肿瘤及肿瘤转移的位点的PET和SPECT成像，同时，可以利用核素切伦科夫辐射发光进行原位的光学成像。但是核素切伦科夫辐射发光以紫外-蓝光为主，生物光学成像效率较低。为此，本项目研究核素切伦科夫辐射稀土纳米核壳材料NaLnF4:x%Eu@NaLnF4（ Ln：Y, Gd, Lu，x = 0, 1, 5 15 30%）发射红光的特性和原理，并且我们发现同样可以通过γ射线激发稀土发光；随后我们在稀土发光材料淋巴成像研究的基础上，构建高转移的乳腺癌模型，以核素切伦科夫辐射激发淋巴中稀土发光，增强转移淋巴结中光学成像的信号，为光指导手术提供提供依据。